Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
4 verified discoveries match your filters.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy…
Primary source cited
Last reviewed
An investigational NSCLC vaccine (BNT116) is being tested in an ongoing, open-label, first-in-human trial (estimated enrollment 320, sponsor BioNTech SE) with multiple treatment cohorts, primarily to establish safety (dose-limiting toxicities,…
Primary source cited
Last reviewed
In the randomized, placebo-controlled ADRIATIC trial, durvalumab given as consolidation therapy after concurrent chemoradiotherapy meaningfully extended both overall survival and progression-free survival compared with placebo in limited-stage small cell lung…
Primary source cited
Last reviewed